Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists’ Experience

Boris Afanasyev; Madina Avtorhanova; Anna Bannikova; Anastasia Bykova; Andrey Chekalov; Sergey Gritsaev; Ivan Kostroma; Alexander Kulagin; Yuriy Kuznetcov; Elena Lepik; Kirill Lepik; Vladimir Melnichenko; Natalia Mikhailova; Ivan Moiseev; Nikita Mochkin; Irina Nemchenko; Tatiana Nikitina; Anna Petrova; Natalia Porfirieva; Olga Pospelova; Anastasia Samoylova; Anna Smirnova; Elena Smirnova; Elnara Tagieva; Ivan Tsygankov; Anna Turkina; Nikita Volkov; Alisa Volkova; Irina Zapreeva; Anastasia Zherniakova; Sam Salek; Esther Oliva; Tatiana Ionova

30 Jul 2020

Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists’ Experience

Patients with haematological malignancies (HM) may experience significantly compromised quality of life (QoL) as a result of the disease and its…

2 Mins

30 Jul 2020

Integrative Analysis of the Genomic Landscape of Hodgkin Lymphoma Using Liquid Biopsies

The genomic landscape of Hodgkin lymphoma (HL) is not well understood because of the scarcity of Hodgkin-Reed–Sternberg cells, which makes conventional…

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib

3 Mins

30 Jul 2020

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies

Venetoclax is a potent, selective, oral inhibitor of B-cell lymphoma-2. It is approved in the USA in combination with azacitidine, decitabine…

2 Mins

30 Jul 2020

Mechanistic Insights into the Inhibition of Regulatory T Cells by Dasatinib in Chronic Myeloid Leukaemia Patients with Clonal Lymphocytosis

Dasatinib is a potent inhibitor of lymphocyte-specific protein tyrosine kinase (Lck), which plays a pivotal role in T-cell receptor (TCR) signalling…

6 Mins

30 Jul 2020

Pregnancy-Related Thromboembolism in Sickle Cell Disease

Haematological disorders are predominant in the tropical and subtropical countries where major problems of sickle-cell disease (SCD) and thalassaemias…

2 Mins

30 Jul 2020

Identification of HIF2α as a Novel Determinant of Acute Myeloid Leukaemia Block of Differentiation Poses its Inhibition as a Potential Therapeutic Opportunity for Acute Myeloid Leukaemia Patients

Signalling via hypoxia inducible factors (HIF)1α and HIF2α is importantly implicated in cancer,1 although it has been predominantly studied in solid…

Initial Anticoagulant Management of Deep Vein Thrombosis

8 Mins

30 Jul 2020

Anticoagulant Management of Deep Vein Thrombosis: Review of Current Approaches

The initial management of deep vein thrombosis is starting to happen in general practice.

1 Mins

30 Jul 2020

Comparison of Decitabine with Venetoclax versus Intensive Chemotherapy Using Propensity Score Matching and Treatment-related Mortality Risk Scoring

Acute myeloid leukaemia (AML) usually presents in older patients over the age of 65 years.1 A large proportion of such patients are frail or have…

6 Mins

30 Jul 2020

Concerns Regarding the Management of β-Thalassaemia Patients in the Era of COVID-19

Many cases of pneumonia clustered in the city of Wuhan, China, were reported in December 2019, and source tracing has showed Huanan Seafood Market, Wuhan, China, as the origin.

Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus

8 Mins

30 Jul 2020

Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disorder resulting from autoantibodies produced by B-cell derived plasma cells.

Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists’ Experience

Integrative Analysis of the Genomic Landscape of Hodgkin Lymphoma Using Liquid Biopsies

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies

Mechanistic Insights into the Inhibition of Regulatory T Cells by Dasatinib in Chronic Myeloid Leukaemia Patients with Clonal Lymphocytosis

Pregnancy-Related Thromboembolism in Sickle Cell Disease

Identification of HIF2α as a Novel Determinant of Acute Myeloid Leukaemia Block of Differentiation Poses its Inhibition as a Potential Therapeutic Opportunity for Acute Myeloid Leukaemia Patients

Anticoagulant Management of Deep Vein Thrombosis: Review of Current Approaches

Comparison of Decitabine with Venetoclax versus Intensive Chemotherapy Using Propensity Score Matching and Treatment-related Mortality Risk Scoring

Concerns Regarding the Management of β-Thalassaemia Patients in the Era of COVID-19

Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus

Therapy Area

About Us